前立腺肥大症に対するステロイド性アンチアンドロゲン剤の応用 --TSAA-328とTSAA-291の臨床治験--

Abstract

A total of 116 patients with benign prostatic hypertrophy have been treated with TSAA-328 (16β-ethyl-17, β-hydroxy-4-estren-3-one acetate) and TSAA-291 (16, β-ethyl-l7, β-hydroxy-4-estren-3-one). The following results were obtained. 1) TSAA-328 and TSAA-291 showed definite anti-prostatic action on the enlarged prostate. 2) Administration of 100 mg/week resulted only in a mild improvement of dysuria, so a dose of 100 mg/week is believed to be insufficient. 3) Administration of 200 mg/week resulted in a decrease of residual urine together with improvement of dysuria, though not to a satisfactory degree. 4) These findings suggest that studies with a dose range of 400-600 mg/week should be conducted.